Pharmaceuticals, Biotechnology and Life Sciences
As OncoRes Medical eyes U.S. entry, medtech heavyweight Renee Ryan joins the Company’s Board of Directors PERTH, Australia–(BUSINESS WIRE)–OncoRes Medical…
New members bring world-class clinical expertise to guide Phase 1b trial of TP-317 in ulcerative colitis ESSEX, Conn.–(BUSINESS WIRE)–#IBD–Thetis Pharmaceuticals,…
Final patient dosed in Phase 1 study of SRG-514 in breast cancer patients undergoing breast-conserving surgery; registrational trial design being…
− Achieved Fourth Quarter and Full Year 2025 Global Net Product Revenues of $995 Million and $2,987 Million, Respectively, Representing…
AlloHeme Identified Cancer Relapse Earlier Than Standard Monitoring Methods in AML and MDS Patients Following Allogeneic HCT Ultra‑Sensitive, Non‑Invasive Surveillance…
New integrated testing approach provides potential to deliver earlier biomarker insights, reduce diagnostic uncertainty in complex cancer cases, and enable…
BASECAMP, a three-month, randomized, double-blind, placebo-controlled study, will evaluate SAT-3247’s safety and tolerability, and effect on muscle force, muscle quality…
FRAMINGHAM, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of three abstracts for presentation at…
Late-breaking KEYNOTE-B15 data show KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response…
Investigation’s preliminary indications are that 2023 and 2024 revenue may have been overstated by less than 2% for each fiscal…